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INTRODUCTION 
 Caesarean section is the commonest major operative procedure 
done in the world. 
 Incidence of caesarean section is increasing throughout the 
world because of social factors like advanced maternal age, 
improved surgical techniques and higher detection of fetal distress. 
 Although caesarean delivery is much safer today due to 
improved techniques but still it is a major cause of intra operative 
and post operative complications with higher morbidity and 
mortality than with vaginal delivery. 
 Although caesarean delivery is more traumatic than an easy 
vaginal delivery but an elective caesarean section is preferred over a 
difficult vaginal delivery to reduce maternal and neonatal morbidity 
and mortality. 
 Obstetric blood loss is one of the feared complications of child 
birth.  Blood loss during caesarean section is twice than that of 
vaginal delivery. During placental delivery the fibrinolytic system 
gets activated which can last for upto 6-10 hours causing post 
partum bleeding. Fibrinolytic activity in the endometrium of patients 
with dysfunctional uterine bleeding will also be high.   
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So, antifibrinolytics will be effective in reducing the blood loss 
during caesarean section and in DUB related menorrhagia. 
 Postpartum haemorrhage contributes to 25% of global 
maternal death. So death due to PPH should be prevented. 
 The present study observes the blood loss reduced by 
Tranexamic acid, an antifibrinolytic agent during and after caesarean 
section. 
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AIM OF THE STUDY 
  
1. To evaluate the efficacy of preoperative parenteral 
tranexamic acid in reducing the blood loss during and  
after caesarean section. 
2. To compare it with the amount of blood loss in patients 
who did not receive tranexamic acid prior to caesarean 
section. 
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REVIEW OF LITERATURE 
Definition of Caesarean Section : 
 Caesarean section is defined as the surgical procedure by 
which baby is delivered after 28 completed weeks of gestation from 
an intact uterus through abdominal and uterine incision. 
Incidence : 
 Caesarean section is the commonest major operative procedure 
done in the world.  Its incidence has been quadrupled between 1965-
1988 because of various factors.  Current rate of caesarean section in 
most of the countries is between 25-40%.  But WHO says that there 
may be no health benefits from caesarean section rates exceeding 
15%. 
 A mandatory second opinion was associated with a small but 
significant reduction in caesarean rate without an adverse effect on 
maternal or perinatal morbidity (Althabe et al 2004). 
 Maternal morbidity dramatically increases with caesarean 
section when compared with vaginal delivery (Burrows et al 2004) 
and the cost of caesarean section increases two fold than that of 
vaginal delivery (Henderson et al 2001).  So, risks and benefits need 
to be weighed. 
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Blood loss during Caesarean Section : 
 Normal blood loss during vaginal delivery may be up to 500 
ml.  But a lower value of 300ml should be considered for Asian 
women as they may be unable to cope up with a large amount of 
blood loss due to their small build and lower antenatal Hb (Ratnam 
and Rauf et al 1989). 
 Blood loss during caesarean section is twice than that of 
vaginal delivery, that is up to 1000 ml (Driffe 1997). 
 
Post partum haemorrhage is defined as, 
1. Blood loss of more than 500 ml following vaginal delivery, 
more than 1000 ml following caesarean delivery and more 
than 1500 ml after caesarean hysterectomy. 
2. Any post partum blood loss which needs blood transfusion 
or causes fall in haematocrit by 10% (ACOG-definition). 
3. Any postpartum blood loss causing haemodynamic 
instability or if untreated leads to haemodynamic 
instability. 
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Incidence of PPH : 
2 to 11% when blood loss is estimated visually (Brant et al 
1967) and 20% when blood loss is estimated by quantitative 
methods (Newton et al 1961). 
 Blood loss estimated by visual observation method will always 
be less than that of actual blood loss (Pritchard 1962). 
Types of PPH : 
¾ Primary PPH Æ PPH occurring within 24 hours after the 
delivery of the baby 
¾ Secondary PPH Æ PPH occurring 24 hours after the delivery 
of the baby to 6 weeks postpartum. 
Factors causing increased blood loss during Caesarean Section : 
 Four basic causes are 4TS. 
1. Tone loss  
2. Trauma  
3. Tissue retention  
4. Thrombotic defect. 
Of these tone loss is common and thrombotic defect is 
difficult to treat. 
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1.  Atonicity / Hypotonicity  - 80% 
 Predisposing factors are 
1. Multiparity 
2. Anaemia / malnutrition 
3. Overdistended uterus – twins, big baby,  polyhydramnios 
4. Prolonged labour followed by caesarean section 
5. Induced labour  
6. Fibroids complicating pregnancy 
7. Inadverent use of oxytocics in labour 
8. Chorioamnionitis 
9. Previous H/o  PPH 
10. Prolonged surgery 
11. Drugs – halogenated anaesthetics, MgSO4 , Nifedipine. 
12. Placenta praevia 
13. Abruptio placenta – couvelaire uterus 
14. Exteriorised uterine closure 
15. Uterine anomalies 
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2.  Trauma – 20 % 
 Trauma often involves uterine vessels when the incision 
extends laterally.  Traumatic factors causing increased blood loss 
are, 
1. Pfannensteil incision 
2. Classical caesarean section 
3. Obstructed labour with deeply engaged head 
4. Big baby 
5. Transverse lie 
6. Emergency caesarean section 
7. Poor obstetrician’s experience 
3. Tissue retention – 10% 
 Placenta accreta, increta and percreta, missed cotyledons and 
succenturiate placental lobe. 
4. Thrombotic defect -  5% 
¾ Inherent bleeding tendencies like VWD, ITP 
¾ Acquired coagulation disturbances like HELLP, abruptio 
placenta, IUD, septicemia–causing DIC. 
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Blood Loss Assessment : 
 In order to reduce the morbidity and mortality of caesarean 
section blood loss it has to be measured accurately.  It can be 
measured by the following methods. 
Clinical Methods Quantitative methods 
1. By subjective characters 1. Gravimetric method 
2. Visual estimation 2. Colorimetric method 
 3. Electrolyte conductivity 
method 
 4. Blood loss by suction 
 5. Blood volume measurements 
 6. Radioactivity method 
 
I -  Estimation by Subjective characters : 
1. Shock Index :  (SI) 
 SI   =  Heart rate / systolic BP.   
Normal value is 0.5 – 0.7. With significant haemorrhage it 
increases to 0.9 to 1.1. 
2. Rule of 30 has been proposed for the general acute 
management of PPH. If the patient’s  
i. Systolic BP falls by 30 mmHg 
ii. Heart rate raises by 30 bpm 
iii. Respiratory rate rises to > 30 / min 
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iv. Hb or HCt drops by 30% 
v. Urine output is < 30 ml / hr  
 then the patient is most likely to have lost atleast 30% of blood 
volume and is in moderate shock. 
3.  Benedetti’s Clinical Blood loss Assessment : 
Class I  (mild shock )  -  15% blood loss 
¾ Mild tachycardia 
¾ Normal BP 
¾ Postural hypotension and weakness 
¾ Looking pale 
Class II (Moderate shock) -  15 to 25% blood loss 
¾ Severe tachycardia 
¾ Fall in BP 
¾ Thirst sensation 
¾ Oliguria 
Class II -  30 – 35% blood loss 
¾ Poor renal and cerebral perfusion resulting in oliguria, 
confusion and restlessness. 
Class IV (severe shock)  > 40% blood loss 
¾ Air hunger (Increased RR) 
¾ Anuria 
¾ ECG abnormalities 
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II – Visual Estimation : 
Advantages : 
¾ Inexpensive 
¾ Rapid 
¾ Continuous method 
Disadvantages : 
¾ Inaccuracy - blood loss assessment by visual estimation is 
always less than the actual blood loss (Pritchard et al 1962). 
¾ Intraobserver variation is high. 
III – Gravimetric Method : 
¾ Patient weighing method 
¾ Swab weighing method 
By measuring the weight of the patient or swabs prior to and 
after surgery. 
1. Patient weighing method Æ allowance must be made for 
drain, dressings, infusion and tissue removal and insensible 
water loss. 
2. Swab weighing method 
¾ 1 gm weight gain = 1ml blood loss (Bonica and Lyter et al 
1951, Harding 1984). 
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¾ Swabs must be weighed as soon as possible so that loss by 
evaporation can be minimized. 
¾ This is the only practically possible and feasible method 
used in our study. 
IV – Colorimetric Method (Roe et al 1962, Thornton et al 1963, 
Rustad et al 1963). 
 The washing of the blood contaminated swabs is carried out in 
a known volume of tap water to which has been added sufficient 
amount of ammonium hydroxide to give a one in 1000 dilution as a 
defoaming agent.  Blood collected in the suction container has to be 
added to the water and the concentration of the resultant solution has 
to be determined. 
               Hb%of the washing fluid x volume of the washing fluid 
Blood loss in ml  = 
                 Hb%of the patient’s blood x dilution factor patient’s Hb 
 
V – Blood loss by Suction : 
 Blood in the suction container can be measured. Inaccuracy in 
this method can be reduced by, 
a) Having measuring cylinder in the suction line 
b) Adding defoaming agent to the container. 
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VI -  Electrolyte Conductivity Method : 
 (Leveen and Rubricius et al 1958) 
 Using automated blood loss meter based on electrolyte 
conductivity. 
VII – Radioactivity Method :  (Murray and Dott’s et al 1960) 
 Intravenous injection of small but known amount of 
radioisotope should be followed by measuring the radioactivity of 
blood on swabs collected during operation. 
VIII – Blood volume measurements : 
a) Dye method – using Evans blue dye which must neither be 
catabolised nor rapidly lost from the circulation. 
b) Radioisotopes like I131 labelled albumin or Cr51 labelled 
RBCS can be used preoperatively and measuring the post 
operative radioactivity by Geiger – Muller count. (Mollison 
and Veall et al 1955). 
Among the above mentioned methods swab weighing method 
and blood loss from suction container are practically possible and 
feasible methods that were used in our study. 
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Reducing the Caesarean section Blood loss : 
 This can be done by the following measures.  
1. Preoperative measures 
2. Intra operative measures 
3. Post operative measures 
Preoperative measures : 
1. Improving pre pregnant Hb% and correcting antenatal 
anaemia 
2. Antenatal Hb% and blood grouping and Rh typing. 
3. 2 IV line / blood reservation for high risk cases. 
4. Avoid excess and prolonged anaesthesia. 
5. Correction of coagulation abnormality before surgery in 
cases of abruptio placenta, IUD and HELLP syndrome. 
6. Using antifibrinolytics prophylactically before surgery. 
Intra operative measures : 
1. Joel Cohen incision – straight transverse incision made 3cm 
above the pubic symphysis in which rectus sheath is 
stretched with fingers without cutting with scissors. 
2. Lower segment caesarean section (avoiding classical 
caesarean section) 
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3. Sharp method of expansion of uterine incision. 
4. Following active management of third stage of labour in 
caesarean section (approved by FIGO in 2003 and 
recommended by WHO in 2006). 
i. Early administration of oxytocics immediately 
after the delivery of the baby (oxytocin 10 units is 
the drug of choice if available  - added to the IV 
drip ) 
ii. Controlled  cord traction after placental separation 
iii. Uterine massage 
5. Interior uterine closure for high risk cases 
6. Avoiding undue prolongation of surgery 
7. Asking the assistant to push the deeply engaged head from 
below upwards. 
8. Making J shaped or inverted T shaped incision in 
obstructed labour 
9. Using Patwarthans or modified Patwarthans method in 
cases of obstructed labour to deliver the baby 
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10. Placental bed drainage would reduce its bulkiness and 
allowing the uterus to contract and retract thereby aids its 
delivery (Roger et al 1993). 
¾ Eventhough AMTSL may decreases the incidence of PPH 
effectively it may be associated with increased nausea and 
vomiting (Prendiville et al 2003). 
¾ Timing of cord clamping is also an important factor which 
decides placental separation (Mc Donald 2003). 
MISGAV LADACH TECHNIQUE :  (Hospital in Jerusalem) 
 This technique is advised in modern obstetrics to reduce post 
operative morbidity and has the following components. 
1. Joel Cohen abdominal wall incision 
2. Exteriorised uterine closure 
3. Single layer uterine closure 
4. No need for peritoneal closure 
5. Rectus muscle should not be approximated. 
Post operative measures : 
1. Proper post operative monitoring of high risk cases 
2. Continuing oxytocics in the immediate post partum period 
for high risk cases. 
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Treatment of PPH during Caesarean Section  
 
General    Specific 
   
  Medical    Surgical 
 
Oxytocics      Haemostatics     Conservative     hysterectomy 
 
 A systematic and stepwise management of PPH can be 
achieved with the use of the mnemonic “HAEMOSTASIS.” 
 
 HAEMO -   General Medical Management 
H - Ask for help 
A - Assess the vital parameters 
E - Establish etiology – 4 TS 
  Ecbolics (oxytocics) 
  Ensure availability of blood 
M - Massage the uterus 
O - Oxytocin and prostaglandins 
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STASIS -   Specific surgical Management 
S - Shift to operation theatre, Bimanual compression and  
  antishock garments if transfer is required 
T - Rule out tissue and trauma and proceed with tamponade  
  test (in vaginal delivery) 
A - Apply compression sutures 
S - Stepwise devascularisation 
I - Interventional radiology (uterine artery embolisation) 
S - Surgery (hysterectomy) 
Oxytocics : 
1. Oxytocin – 10 units IM/IV infusion should be given 
immediately after baby delivery.   
2. Methyl ergometrine : 0.2 mg IV /IM can be repeated every 15 
minutes to a maximum of 5 doses. Contraindicated in heart 
disease and hypertensives.   
3. 15 methyl PGF2α  - 250 µg IM  can be repeated every 15 
minutes to a maximum of 8 doses. It can also be given intra 
myometrially. It is contraindicated in bronchial asthma 
patients. 
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4. Misoprostol (PGE1) – 600 – 1000µg can be given by intra 
rectal, vaginal, intra cervical routes. Main side effect is 
shivering and hyperpyrexia. 
5. Syntometrine -  5 units oxytocin with 0.5 mg ergometrine 
maleate – given IM. 
    rFVII 
Haemostatics         EACA (Epsilon  
         Amino caproic acid) 
    Antifibrinolytics  
        Tranexamic acid 
rFVII (Recombinant Factor VII) 
¾ Produced by recombinant technology by transfecting the liver 
gene into baby hamster kidney cell line. 
¾ Useful in coagulopathic bleeding 
¾ Advantage -  No viral contamination  
¾ Disadvantage – cost 
Antifibrinolytics :  
As the fibrinolytic system gets activated after placental 
delivery and also in menorrhagia, antifibrinolytics are useful in 
treating PPH and DUB. 
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 Delayed severe and prolonged haemorrhage from the placental 
site several hours post delivery may respond to antifibrinolytic 
therapy if all other measures fail (Bonnar et al 1981). 
 Tranexamic acid can be given antenatally by oral route for one 
week to treat women with history of recurrent abruption to get 
successful neonatal outcome. (Astedt – Nilsson et al 1978). 
 Tranexamic acid can be used safely and effectively to reduce 
bleeding resulting from caesarean section.  (Tatsumoto K et al 2004, 
Sekhabat et al). 
 Tranexamic acid significantly reduces the amount of blood 
loss during and after caesarean section without any side effects or 
complications like thrombosis (Gobel Mayer et al 2007). 
 Prophylactic use of tranexamic acid antenatally in women with 
bleeding disorders was not associated with any thrombogenic side 
effects (Lindoff C et al 1993). 
 Antifibrinolytic tranexamic acid when used preoperatively 
reduces perioperative allogenic blood transfusion  (Cochrane data 
base 2001). 
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 Antifibrinolytic tranexamic acid when used preoperatively 
reduces perioperative blood loss in spine surgery (Laporte S et al 
2006). 
 Antifibrinolytic tranexamic acid reduces fibrinolytic bleeding 
in DUB ( Duckitt et al 2005). 
 Tranexamic acid decreases the heavy bleeding in DUB 
patients (Mc culy et al 2007). 
 Tranexamic acid reduces heavy bleeding in DUB patients with 
menorrhagia (Cochrane data base 2003). 
Tranexamic acid effectively reduces the blood loss and blood 
replacement in total knee replacement surgery (Department of 
orthopaedic surgery, Sriraj Hospital, Mahidol University, Bangkoh 
10700). 
Tranexamic acid and aprotinin reduce post operative bleeding 
and transfusions during primary coronary revascularisation  (Robert 
S. Brown et al). 
Tranexamic acid and EACA can be used before dental 
extraction in haemophilia patients to reduce the bleeding 
prophylactically.  (Walsh PN and Evans BE et al  1975). 
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Tamponade Test 
 (Katesmark et al 1994) 
    Chan et al 1997) 
 Can be done using Sengstaken blackmore tube either 
diagnostically or therapeutically. 
¾ If bleeding stops after inflating the bulb Æ  Therapeutic  
– no further  surgical intervention needed 
¾ If bleeding continues Æ Diagnostic     
 -   further surgery is indicated 
Conservative Surgeries : 
1. Placental bed suturing (Arulkumaran et al 1999). 
2. B Lynch (Lynch et al 1997) pair of vertical brace sutures 
around the uterus to oppose the anterior and posterior walls 
and to apply continuous compression. 
3. Modified B Lynch (Haymann et al 2002).  Similar pair of 
vertical brace sutures without opening the uterine cavity. It 
also includes cervico isthmic horizontal opposition sutures. 
4. Cho’s multiple square technique (Cho et al 2000). 
5. Uterine artery ligation (O leary et al 1962). 
6. Stepwise devascularisation (Mal abdrabo et al 1994). 
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¾ Uterine artery ligation (O Leary et al 1962). 
¾ High and low level uterine artery ligation (Dutta et al 
1999). 
¾ Ovarian artery ligation. 
¾ Internal illiac artery ligation (still 1999). 
Internal illiac artery ligation (still 1999) 
¾ Controls uterine and vaginal bleeding 
¾ Results in 85% reduction in pulse pressure and 50% reduction 
in blood flow and converts the arterial pressure system into a 
venous system. 
¾ 40% success rate. 
Uterine Artery embolisation (Ravina et al 1999) 
¾ Polyvinyl alcohol or gel foam particles are injected into 
uterine arteries via femoral artery catheterization. 
¾ 85 – 95% success rate. 
Hysterectomy  
 Done as a final resort when all measures fail.  
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PHARMACOLOGY OF TRANEXAMIC ACID 
 Tranexamic acid is a synthetic derivative of aminoacid lysine.  
It is an antifibrinolytic haemostatic agent which controls all types of 
bleeding mainly coagulopathic bleeding. 
Chemical Structure : 
It is a Trans – 4 – amino methyl cyclohexane carboxylic acid 
(AMCA). Molecular Weight  – 157.2 
       C8  H15 NO2    
 
 
 
 
 
 
 It is a white crystalline powder. Aqueous solution for injection 
has a pH of 6.5 – 8. 
Pharmacodynamics : 
 Fibrin is the basic framework for clot formation to maintain 
haemostasis. This clot has to be lysed after a particular period of 
time by fibrinolysis by the following way. 
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   Endothelial Cell 
 
 
Protein  C       Activated protein C 
 
 
 Activated VIII  Inactive    Activated   Inactive 
        VIII         V       V 
 
 
     Inactivates inhibition of tissue  
plasminogen activator 
                 
                   
            
                 Plasminogen                  Plasmin  
         
          (-)         
       TXA        Fibrinolysis 
 
   
        FDP formation 
 
 Tranexamic acid acts as an antifibrinolytic agent by the 
following 2 ways. 
1. Reversible, competitive blockage of lysine binding sites on 
plasminogen, so that plasminogen activator cannot bind 
with plasminogen Æ at lower doses. 
Thrombomodulin and 
Thrombin 
 
(-) TXA 
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2. Non competitive inhibition of proteolytic action of plasmin 
similar to EACA.  8-10 times more potent than EACA as it 
binds strongly with both strong and weak receptors. 
At therapeutic concentration (1mg/ml) it will not cause platelet 
aggregation. 
Pharmacokinetics : 
¾ Oral absorption is 30-50%. It is not affected by food 
¾ Only 3% is plasma protein (globulin) bound. Remaining binds 
with plasminogen. It will not bind with serum albumin. 
¾ Only 5% will be metabolized in liver. Remaining 95% of the 
drug will be excreted via urine unchanged. 
¾ T ½ Æ 2- 10 hours.  90% of the drug is excreted in urine 
within 24 hours of administration. 
¾ Rapidly enter into joint fluid 
¾ Crosses the placenta and blood brain barrier 
¾ 1% of serum level will be achieved in breast milk. 
Indications : 
 This antifibrinolytic agent can be used in all types of bleeding 
especially coagulopathic bleeding. It can also be used 
 32
prophylactically before surgical procedures where excess bleeding 
will be expected. 
1. HELLP, DIC, Thrombasthenia related bleeding  
2. Postpartum haemorrhage 
3. Dental extraction in haemophilia patients 
4. Orthopaedic surgeries like spine surgery and total knee / hip 
replacement  
5. Caesarean section 
6. Cardiac surgeries 
7. Trans urethral resection of prostate  
8. Epistaxis 
9. Liver transplantation surgery 
10. First line nonhormonal treatment for menorrhagia in DUB / 
fibroid 
11. Hereditary angioneurotic oedema where it decreases the 
attacks by decreasing plasmin induced complement 
activation. 
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Contraindications : 
1. Previous H/O thromboembolism or active intravascular 
clotting or patients with inherited or acquired thrombophiliac 
states. 
2. Renal failure 
3. Liver failure 
4. Patients with defective colour vision 
5. Subarachnoid haemorrhage – because cerebral oedema and 
infarction may occur rarely. 
Side effects : 
1. Nausea, vomiting, diarrhoea – commonest side effect, occurs 
in > 10% cases 
2. Giddiness and hypotension – if given by sudden rapid iv 
occurs in 1-10% of cases 
3. Defective colour vision – if used for long time 
4. Thromboembolism – rare 
5. Drug allergy – rare 
Monitoring : 
 LFT / RFT and colour vision should be checked periodically if 
used for long time. 
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Should be used with caution in, 
1. Drug allergy patients 
2. Renal / liver disease patients 
3. Elderly individuals with impaired renal function 
4. Pregnancy – as this is a category B drug 
Tranexamic acid can be safely used in lactating mothers, because 
1. 1% of maternal serum level will be reached in breast milk 
2. Only 30-50% absorption occur orally 
PREPARATIONS AND DOSAGE : 
1. Oral -  500 mg tablets  available 
  - 25 mg / kg – thrice daily for one week 
2. Intravenous 
¾ Available preparations contain 100 mg / ml (5ml and 10ml 
ampoules) 
¾ Dose – 10 mg /kg either direct slow IV or after diluting with 
20 ml of 5% dextrose at a rate not more than 1 ml / min.  This 
loading dose can be followed by 1mg / kg / hour IV infusion 
or 10 mg / kg – thrice daily IV. 
¾ It can be mixed with aminoacids, electrolytes or carbohydrate 
solution but not with blood or solutions having penicillin. 
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3. Mouthwashes containing tranexamic acid are also available 
and used for haemophilia patients before and after dental extraction 
because oral mucosa and saliva are rich in plasminogen activator. 
* Dose should be adjusted according to creatinine clearance,  
creative clearance   50 – 80 ml / min -  50% of total dose 
      10-50 ml/min     -  25% of total dose 
       < 10 ml / min    -  10% of total dose 
Storage : 
 Should be stored at 25oC (Room temperature) in a cool, dry 
place and should be kept away from heat or sunlight. 
Drug Interactions : 
1. Chlorpromazine increases cerebral vasospasm when 
combined with Tranexamic Acid, so it should not be 
combined. 
2. Factor IX when given along with Tranexamic Acid there 
will be increased thrombosis risk. So it should not be 
combined. 
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MATERIALS AND METHODS 
 
 The subjects of this prospective randomised placebo controlled 
study were 100 pregnant women who were admitted in the labour 
ward and planned for caesarean section at Government Rajaji 
Hospital, Madurai in the time period from May 2009 to November 
2009 (6 months).   
 In all patients detailed history – medical history, obstetric 
history were taken. Vital parameters checked and basic 
investigations done.  Weight of the patient checked.  Detailed 
general examination and obstetric examination done.  Gestational 
age confirmed by USG.   
 50 patients were placed in group A and 50 patients were 
placed in group B. All patients were counselled and informed 
consent obtained.  
Group A received : 
1. Inj. Tranexamic acid 10 mg/kg slow direct iv over 5 min – 
20 minutes before skin incision. 
2. 0.4 mg methyl ergometrine direct iv and oxytocin 10 units 
in iv infusion immediately after the delivery of the baby. 
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Group B received 
1. Placebo injection of normal saline 5 ml 20 minutes before 
skin incision. 
2. 0.4 mg methyl ergometrine direct IV and oxytocin 10 units 
in iv infusion immediately after the delivery of the baby. 
Inclusion Criteria : 
1. Primi  and 2nd gravida 
2. More than 38 weeks of gestation. 
3. Elective  and emergency  cases with spontaneous onset of 
labour. 
Exclusion Criteria : 
 Women with risk factors for PPH were not included in this 
study. 
1. Haemoglobin  <  8gm% 
2. Twin pregnancy 
3. Polyhydramnios 
4. EFW > 4 kg 
5. Previous H/O PPH 
6. Fibroid complicating pregnancy 
7. Preeclampsia 
8. Placenta previa 
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9. Abruptio placenta 
10. Induced labour 
11. Prolonged and obstructed labour 
12. Heart disease complicating pregnancy 
13. Renal / liver disease patients 
14. Patients on anticoagulants 
15. Previous H/O thromboembolism 
16. Gravidity  > 3 
Methods : 
 Group A and Group B patients received the injections as above 
mentioned.  In each case the following parameters were noted. 
1. Preoperative  PR / BP / RR / Hb% 
2. Intra operative blood loss from placental delivery to end 
of surgery.   
3. Post operative blood loss from the end of surgery to 2 
hours post partum. 
4. Post operative PR, BP, RR, Hb% 
5. Side effects of the drug 
6. Maternal needs for blood transfusion were noted. 
7. Post operative period and the maternal outcome till 
discharge were noted. 
8. Neonatal outcome was also noted. 
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Measurement of Blood loss : 
 In our study blood loss was measured by measuring the blood 
in the suction container after placental delivery and by weighing the 
swabs before and after surgery. 
 1 gm of swab weight = 1 ml of blood 
(Bonica and Lyter 1951 / Harding 1984) 
                Swab weight         –         Swab weight    
Total blood loss        =   after surgery(gm)    before surgery(gm) 
 (ml)    
 +  
Blood in the suction container (ml) 
 
Eventhough this gives only the approximate amount of blood 
lost it is the only practically possible and feasible method. So these 
methods were used in our study. 
 After collecting all the data, the data were tabulated in a 
master chart and analysed.  Data analysis was done with the help of 
computer using Epidemiological information package (2008). 
 Using this software frequencies, percentage, mean, Standard 
Deviation, chisquare and ‘p’ values were calculated.  Kruskul Wallis 
chi square test was used to test the significance of difference 
between quantitive variables and Yate’s test for qualitative variables.  
A ‘p’ value less than 0.05 is taken to denote significant relationship. 
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A -  PROFILE OF CASES STUDIED 
Table 1 – Age Distribution 
No of Cases in 
Group-A Group-B 
Age in Years 
No % No % 
Less than 20 2 4 2 4 
20-24 23 46 25 50 
25-29 22 44 20 40 
30 and above 3 6 3 6 
Total 50 100 50 100 
Mean 
SD 
24.8 Years 
3.2 Years 
24.5 Years 
3.6 Years 
P                                                0.6011  (Not significant) 
 
 The Mean age of the cases in both the group doesn’t differ 
significantly. 
 48% (24/50) of the patients belong to the age group of 20-24 
years and 42% (21/50) of the patients belong to the age group of   
25-29 years. 
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Table 2 – Antenatal care 
No of Cases in 
Group-A Group-B 
Antenatal 
care 
 No % No % 
Booked 20 40 22 44 
Unbooked 30 60 28 56 
Total 50 100 50 100 
P 0.8394 (Not Significant) 
 
 Antenatal booking does not differ in both groups significantly.  
 60% (30/50) of the patients in group A and 56% (28/50) of the 
patients in group B were unbooked. 
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Table 3 – PARITY 
 
No of Cases in 
Group-A Group-B 
PARITY 
 
No % No % 
PRIMI 12 24 17 34 
2nd Gravida 38 76 33 66 
Total 50 100 50 100 
P 0.378  (Not significant) 
 
12 patients in group A and 17 patients in group B were primi 
gravida (29%). 
38 patients in group A and 33 patients in group B were 2nd 
gravida (71%) . 
Both were comparable in both groups. 
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Table 4 - Subjective characters 
 
Group-A Group-B Characters 
Mean SD Mean SD 
‘p’ 
Height (cms) 158.7 6.9 158 4.4 0.1741 
(Not Significant) 
Weight(Kg) 55.7 5.5 56 4.7 0.8682 
(Not Significant) 
BMI 22.1 1.6 22.4 1.3 0.4339 
(Not Significant) 
 
 The average height in group A was 158.7 cm and in group B 
was 158 cm. Average weight  in group A was 55.7kgs and in group 
B was 56 kgs. 
Subjective characters doesn’t differ significantly in between 
the two groups and all parameters were comparable between the two 
groups. 
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Table 5 – Type of Surgery 
 
No of Cases in 
Group-A Group-B 
Type of 
Surgery 
 No % No % 
Emergency 17 34 11 22 
Elective 33 66 39 78 
Total 0.2655 (Not Significant) 
 
 66% of the cases in group A and 78% of the cases in group B 
underwent elective caesarean section. 34% of the cases in group A 
and 22% of the cases in group B underwent emergency caesarean 
section. 
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B :  COMPARISION BETWEEN THE TWO GROUPS 
Table 6 – Changes in vital Parameters 
 
No of Cases in 
Group-A Group-B 
‘p’ Parameters 
 
Mean SD Mean SD  
Pulse rate (per Min) 
  Pre operative  
  Post operative 
  Change 
  % of Change 
 
82.5 
84.4 
1.9 
2.3 
 
1.8 
1.9 
1.3 
1.5 
 
82.2 
87.2 
5.5 
6.7 
 
2.2 
3.1 
2.8 
3.5 
 
0.2534(NS) 
0.0001(S) 
0.0001(S) 
0.0001(S) 
Systolic BP(mm/Hg) 
  Pre operative  
  Post operative 
  Change 
  % of Change 
 
115.0 
114.04
-0.96 
-0.81 
 
5.2 
5.1 
2.66 
2.21
 
116.5 
113.1 
-3.4 
-2.84 
 
5.2 
4.8 
4.45 
3.71 
 
0.2479-NS 
0.2372-NS 
0.0024-S 
0.0023-S 
Diastolic BP (mm/Hg) 
  Pre operative  
  Post operative 
  Change 
  % of Change 
 
74 
74.02 
0.02 
0.03 
 
7.6 
5.4 
7.2 
3.2 
 
 
78.5 
74.3 
-4.2 
-5.2 
 
4.6 
5.2 
4.5 
5.7 
 
0.0022-S 
0.762-NS 
0.0001-S 
0.0001-S 
Respiratory rate (per min)  
Pre operative  
  Post operative 
  Change 
  % of Change 
 
18.64 
18.92 
0.28 
1.56 
 
1.31 
1.35 
0.7 
3.92
 
18.4 
18.52 
0.12 
0.75 
 
 
1.71 
1.66 
0.63 
3.92 
 
0.4024-NS 
0.1825-NS 
0.0912-NS 
0.0998-NS 
 
S -  Significant                        NS – Not Significant 
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Mean increase in pulse rate in group A was 1.9/min and in 
group B was 5.5/min.  Mean fall in systolic BP in group A was -
0.96mmHg and in group B was -3.4mmHg.  Mean fall in diastolic 
BP in group  B  was -4.2mmHg and mean increase in diastolic BP in 
group A was 0.02 mmHg.  Mean increase in RR in group A was 0.28 
and in group B was 0.12.   
 PR increases and BP decreases significantly in group B 
compare with group A post operatively. RR increases post 
operatively more in group B than in group A but without statistical 
significance. 
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Table 7 -   Changes in Hb - gms% 
Group-A Group-B Hb - gms% 
 Mean SD Mean SD 
‘p’ 
Pre operative 9.12 0.53 9.27 0.47 0.0516 
Not Significant 
Post operative 9.04 0.49 8.79 0.38 0.0348 
Significant 
Change -0.08 0.11 -0.48 0.25 0.0001 
Significant  
% of Changes -0.81 1.14 -5.16 2.5 0.0001 
Significant 
 
Post operative haemoglobin was significantly reduced in 
control group compare to study group. 
Mean fall of Hb% in group A was -0.08 and in group B was  
-0.48. 
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Table 8 – Blood Loss 
Group-A Group-B Blood Loss 
(ml) Mean SD Mean SD 
‘p’ 
PD – EOS 246.6 29.6 354.8 29.9 0.0001 
Significant 
EOS-2 hr/pp 46.2 6.5 79 7.2 0.0001 
Significant 
PD – 2 hr/pp 292.8 32.6 433.8 34.1 0.0001 
Significant 
 
PD - Placental Delivery 
EOS - End of surgery 
2hr PP- 2 hours postpartum 
 Blood loss was significantly high in control group compare to 
study group in all periods. 
 Mean total blood loss in group A was 292.8 ml and in group B 
was 433.8 ml. 
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Table - 9 
  Total blood loss 
No of Cases in 
Group-A Group-B 
Total blood loss  
No % No SD 
< 500ml 49 98 46 92 
> 500ml 1 2 4 8 
Total 50 100 50 100 
P 0.1811  (Not Significant) 
 
 Total blood loss of more than 500 ml was more in control 
group than in study group, but without statistical significance. 
 98% (49/50) of patients in Group A had  < 500 ml blood loss. 
Only 2% (1/50) of patient in Group A had > 500 ml blood loss  
whereas 8% (4/50)  of patients in Group B had > 500 ml blood loss. 
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Table 10 – Maternal blood transfusion 
No of Cases in 
Group-A Group-B 
Maternal blood 
transfusion 
No % No % 
Given 1 2 4 8 
Not given 49 98 46 92 
Total 50 100 50 100 
P 0.1811  (Not Significant) 
 
 Need for maternal blood transfusion doesn’t differ 
significantly between the two groups. 
 1 patient in group A and 4 patients in group B needed blood 
transfusion. 
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Table 11 –   Maternal Complications 
No of Cases in 
Group-A Group-B 
Maternal 
Complication
No % No % 
Vomiting 5 10 3 6 
Fever 1 2 4 8 
Total 6 12 7 14 
  P     0.5698 (not significant) 
 
 5 patients in group A and 3 patients in group B had post 
operative vomiting.  One   patient in group A and 4 patients in group 
B had fever post operatively. 
 This doesn’t have statistical significance. 
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Table - 12  
Hospital stay after 8th POD 
 
No of Cases in 
Group-A Group-B 
Hospital stay after  
8th POD 
No % No % 
Yes 0 0 2 4 
No 50 100 48 96 
P            0.2475    (Not significant) 
                                                    POD – Post operative day 
 2 patients stayed after 8th POD in group B and none of the 
patients in group A were stayed after 8th POD.  This doesn’t have 
any statistical significance. 
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Table - 13  
 NICU Admission 
No of Cases in 
Group-A Group-B 
NICU 
Admission 
 No % No % 
Yes 1 2 2 4 
No 49 98 48 96 
P             0.5  (Not Significant) 
 
 NICU admission doesn’t differ significantly between the two 
groups .One  baby in group A and 2 babies in group B needed NICU 
admission. 
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DISCUSSION 
 As obstetric blood loss contributes to one fourth of global 
maternal death, death resulting from PPH should be avoided. 
 As the fibrinolytic system gets activated after placental 
delivery antifibrinolytic agents can be used to reduce obstetric blood 
loss. 
 As prevention is always better than cure regarding PPH- an 
antifibrinolytic agent tranexamic acid was used prophylactically in 
our study to observe its efficacy in reducing blood loss during and 
after caesarean section. 
1.  Maternal age  :  In our study, the age group of patients included 
varied from 18 to 35 years. Maximum percentage of patients belong 
to the age group of 20-24 years.  40% of group A and 50% group B 
were between 20-24 years. In a study conducted by department of 
Obst & Gynae Medical college and SSG hospital, Baroda, Gujarat 
the mean age was 24 years. 
2. Antenatal Care :  In our study, 40% of group A and 44% of 
group B were booked.  60% of group A and 56% of group were 
unbooked.  In a similar study conducted by International Medical 
Communication Department, Daiichi Pharmaceutical Co. Ltd,  
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Tokyo, Japan,  66% of study group and 68% of control group were 
booked.  Proper antenatal care is important to identify the high risk 
factors in the antenatal period itself and to correct them thereby 
reducing the incidence of PPH. 
3.  Parity :   In our study, second gravida were more in both groups 
than primigravida. All were Singleton pregnancies.  In group A 24% 
were Primigravidas and 76% were 2nd gravidas.  In group B – 34% 
were Primigravidas and 66% were 2nd gravidas.  In a similar study 
conducted by Department of obst & Gynec Medical College and 
SSG hospital, Baroda, Gujarat  also second gravidas were  70%  and 
primigravidas were  30%.      
4.  Subjective characters :  In our study mean height was 158.7 cm 
in group A and 158 cm in group B. Mean weight was 55.7 kg in 
group A and 56 kg in group B.  Mean BMI was 22% in group A and 
22.4 in group B.  In a similar study conducted by Department of Obs 
& Gyne of Peking Union Medical College hospital, Chinese 
academy of Medical Sciences, Beijing 100730, China, where mean 
height was 161 cm and mean weight was 72 kg. 
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5.  Type of Surgery : In our study, 34% of group A and 22% of 
group B were emergency cases.  66% of group A and 78% of group 
B were elective cases. Both were comparable in both groups. 
6.  Vital parameters :  In our study, mean  postoperative    increase 
in PR was 1.9 in group A and 5.5 in group B.  Mean  postoperative    
fall in SBP was - 0.96 in group A and -3.4 in group B.  Mean  
postoperative  increase in RR was 0.28 in group A and 0.12 in group 
B.  There was a significant fall in SBP and rise in PR without any 
significant change in RR post operatively.  In a similar study 
conducted by International Medical Communication department, 
Daiichi Pharmaceutical Co. Ltd, Tokyo, Japan also there was a 
statistically significant change in vital parameters. 
7.  Blood loss :  In our study, there was a statistically significant 
reduction of blood loss in both periods, that is from placental 
delivery to end of surgery and also from the end of surgery to two 
hours post partum.  Mean blood loss from PD to EOS in group A 
was 246.6 ml and in group B was 354.8 ml.  Mean blood loss from 
the end of surgery to 2 hour post partum was 46.2 ml in group A and 
79ml in group B.  Mean total blood loss was 292.8ml in group A and 
433.8 ml in group B.  In contrast in a study conducted by Shanghai 
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International Peace Maternity and Child health hospital, Shanghai, 
China also blood loss was reduced in both periods.  But the blood 
loss reduction from PD-EOS was not statistically significant and 
from EOS to 2 hours post partum and the total blood loss reduction 
were with statistical significance. 
8.  Haemoglobin change :  In our study statistically significant fall 
in Hb% occurred after surgery in  group B than with group A.  Mean 
fall of Hb% in group A was -0.08 and in group B was -0.48.  In 
contrast in a similar study conducted by Beijing Obst and Gyn 
hospital, Beijing, China there was also more post operative fall in 
Hb% in the control group than with the study group but without 
statistical significance between study and control groups. 
9.  Total blood loss of more than 500 ml and need for maternal 
blood transfusion. 
 In our study, one patient in group A and 4 patients in group B 
had total blood loss of more than 500 ml who needed blood 
transfusion.  This need was not statistically significant.  In a similar 
study conducted by University Department of Obs & Gyn, Rosie 
Maternity hospitals, Robinson way Cambridge – CB2 – 2SW – UK,  
2 patients in study group and 5 patients in control group had more 
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than 500 ml of total blood loss and needed blood transfusion.  This 
was also without statistical significance. 
10.  Maternal complications other than blood loss. 
 In our study, 5 patients in group A and 3 patients in group B 
had vomiting in the immediate post operative period which may be 
related to the drug.  But this increased incidence of vomiting in 
group A was not statistically significant.  One patient in group A and 
4 patients in group B had fever on 3rd post operative day.  Group A 
patient with fever had dysuria and urine culture was positive for 
E.coli and treated with antibiotics and discharged on 8th POD. 
 Among 4 patients, who had fever on the 3rd POD in group B – 
2 had breast engorgement as their babies were admitted in NICU. 
One baby was discharged on 1st POD and another one was on 5th 
POD. After the discharge of the babies, fever subsided in both 
patients. Remaining two patients in group B with fever had purulent 
wound discharge on 5th POD when the dressing was changed.  Pus 
culture and sensitivity done and treated with appropriate antibiotics 
and daily dressing and discharged on 15th and 16th POD.  
Eventhough the higher incidence of wound infection in group B was 
not statistically significant it may be due to minimal blood collection 
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in the wound in group B.  None of the patients in both groups had 
thromboembolic complications postoperatively. 
11.  Neonatal Outcome : 
 In our study, neonatal outcome were comparable in both 
groups. One baby in group A needed NICU admission for HIE stage 
I and the indication for LSCS was unengaged head with foetal 
distress and discharged on 5th POD. 
 2 babies in group B needed NICU admission for HIE Stage I 
and for transient tachypnoea of the newborn the indications for 
LSCS being unengaged head with foetal distress in one and previous 
LSCS with PROM in another.  They got discharged on 1st and 5th 
POD.  The inference was that tranexamic acid use was not 
associated with any impact on neonatal outcome in our study.  In a 
similar study conducted by Department of Obs & Gyn King’s 
College hospital, London, there was no significant difference in the 
neonatal outcome between study and control groups. 
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SUMMARY 
¾ This study was conducted in the Department of Obstetrics and 
Gynaecology, Government Rajaji Hospital, Madurai to clinically 
observe the blood loss reduced by tranexamic acid during and 
after caesarean section. 
¾ 100 patients were selected for the study, 50 as study group (A) 
and 50 as Control group (B). 
¾ 48% of the cases belong to the age group 20 – 24 years. 
¾ 29% of the cases were primigravida and 71% of the cases were 
2nd gravida. 
¾ 28% of the cases were emergency cases and 72% of the cases 
were elective cases. 
¾ There was no statistically significant difference in the subjective 
characters in between the two groups. 
¾ Tranexamic acid significantly reduced the blood loss from 
placental delivery to 2 hour post partum. 
¾ There was statistically significant fall in blood pressure and rise 
in PR without any significant change in RR in the control group 
compare to the study group. 
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¾ Hb level was significantly reduced in the control group compare 
to the study group postoperatively but without significant increase 
in the need for blood transfusion. 
¾ Incidence of vomiting was higher in the study group and wound 
infection was higher in the control group but without statistical 
significance.  This vomiting may be drug related and wound 
infection may be related to blood collection in the wound.  None 
of the patients in both the groups had thromboembolic 
complications postoperatively. 
¾ Neonatal outcome was similar in both the groups. 
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CONCLUSION 
 
 Tranexamic acid injection, an antifibrinolytic agent when 
given prophylactically 20 minutes before skin incision by 
intravenous route appears to reduce the blood loss during and 
after caesarean section effectively. 
 Some studies demonstrated that tranexamic acid minimally 
increases the risk of thromboembolism but without statistical 
significance which was not observed in our study. 
 So, further studies are also needed to support its efficacy. 
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PROFORMA 
Name :    Age :   IP No.: 
AN Care : Booked / Unbooked 
Height :    Weight :  BMI  : 
Obstetric Table  : 
Date and Time of Admission  : 
Past History   : 
Menstrual History  : 
Marital History   : 
Obstetric History   : 
General Examination  : 
PR / minute   : 
BP mm/Hg    : 
RR / minute   : 
CVS     : 
RS     : 
Abdominal examination : 
Vaginal examination  : 
Basic investigations  : 
 Hb % 
 Urine  
Albumin 
Deposits 
Sugar 
 Blood urea  
  Sugar 
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 Sr.Creatinine 
 
 Blood Grouping / typing 
 PPTCT 
 LFT 
 Clotting time   
Obstetric USG :  
Date and Time of Surgery : 
Indication for surgery     :  
Intra operative blood loss  : Placental delivery to EOS (ml) 
Post operative blood loss  :    EOS – 2 hrs  PP (ml) 
Total blood loss (ml)     : 
2 hours post partum PR   / min 
    BP   mm/Hg 
    RR  / min 
3rd POD   Hb  gm% 
Maternal blood transfusion  : Yes / No 
Maternal complication   :  
Neonatal Outcome   : 
Date & Time of discharge  : 
Duration of hospital stay  : 
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ABBREVATIONS 
PR PULSE RATE 
SBP SYSTOLIC BLOOD PRESSURE  
DBP DIASTOLIC BLOOD PRESSURE 
RR RESPIRATORY RATE 
HT HEIGHT 
WT WEIGHT 
BMI BODY MASS INDEX 
PD PLACENTAL DELIVERY 
EOS END OF SURGERY 
PP POST PARTUM 
HB HAEMOGLOBIN 
POD POST OPERATIVE DAY 
NICU NEONATAL INTENSIVE CARE UNIT 
LFT LIVER FUNCTION TEST 
RFT RENAL FUNCTION TEST 
EL ELECTIVE 
EM EMERGENCY 
IUD INTRA UTERINE FETAL DEATH 
AMTSL ACTIVE MANAGEMENT OF THIRD STAGE OF LABOUR 
VWD VON WILLEBRAND’S DISEASE 
ITP IDIOPATHIC THROMBOCYTOPENIC PURPURA 
DIC DISSEMINATED INTRA VASCULAR COAGULATION 
DUB DYSFUNCTIONAL UTERINE BLEEDING 
TXA TRANEXAMIC ACID 
CVS CARDIO VASCULAR SYSTEM 
RS RESPIRATORY SYSTEM 
HELLP HEMOLYSIS, ELEVATED LIVER ENZYMES, LOW 
PLATELETS 
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SUCTION APPARATUS 
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ELECTRONIC WEIGHING MACHINE 
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TRANEXAMIC ACID 
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No % No %
Booked 20 40 22 44
Unbooked 30 60 28 56
No % No %
PRIMI 12 24 17 34
2nd Gravida 38 76 33 66
Mean SD Mean SD
Height (cms) 158.7 6.9 158 4.4
Weight(Kg) 55.7 5.5 56 4.7
BMI 22.1 1.6 22.4 1.3
Age in Years No of Cases in
Group-A Group-B
Antenatal care No of Cases in
Group-A Group-B
PARITY No of Cases in
Group-A Group-B
Characters Group-A Group-B
Characters
Height (cms)
Weight(Kg)
BMI
Characters GroupA Group B
Height (cms) 158.7 158
Weight(Kg) 55.7 56
BMI 22.1 22.4
No % No %
Emergency 17 34 11 22
Elective 33 66 39 78
Mean SD Mean SD
  Pre operative 82.5 1.8 82.2 2.2
  Post operative 84.4 1.9 87.2 3.1
  Pre operative 115 5.2 116.5 5.2
  Post operative 114.04 5.1 113.1 4.8
  Pre operative 74 7.6 78.5 4.6
  Post operative 74.02 5.4 74.3 5.2
  Pre operative 18.64 1.31 18.4 1.71
  Post operative 1.56 3.92 0.75 3.92
Characters
Type of Surgery No of Cases in
Group-A Group-B
Parameters No of Cases in
Group-A Group-B
82.5 82.2
84.4 87.2
115 116.5
114.04 113.1
74 78.5
74.02 74.3
18.64 18.4
1.56 0.75
Pre Op Post Op Pre Op Post Op
Pulse Rate 82.5 84.4 82.2 87.2
Systolic BP 115 114 116.5 113.1
Diastolic BP 74 74 78.5 74.3
Respiratory Rate 18.6 18.9 18.4 18.5
Mean SD Mean SD
Pre operative 9.12 0.53 9.27 0.47
Post operative 9.04 0.49 8.79 0.38
Hb -gm% Group A Group B
Pre operative 9.12 9.27
Post operative 9.04 8.79
Mean SD Mean SD
PD – EOS 246.6 29.6 354.8 29.9
EOS-2 hr/pp 46.2 6.5 79 7.2
PD – 2 hr/pp 292.8 32.6 433.8 34.1
GroupA Group B
Vital Parameters
Hb - gms% Group-A Group-B
Blood Loss (ml) Group-A Group-B
Blood Loss (ml) Group A Group B
PD – EOS 246.6 354.8
EOS-2 hr/pp 46.2 79
PD – 2 hr/pp 292.8 433.8
No % No SD
< 500ml 49 98 46 92
> 500ml 1 2 4 8
No % No %
Given 1 2 4 8
Not given 49 98 46 92
Maternal blood transfusion Group A Group B
Given 1 4
Not given 49 46
No % No %
Vomiting 5 10 3 6
Fever 1 2 4 8
Total bloodloss No of Cases in
Group-A Group-B
Maternal blood 
transfusion
No of Cases in
Group-A Group-B
Maternal Complication No of Cases in
Group-A Group-B
Hospital stay after 
8th POD
No % No %
Yes 0 0 2 4
No 50 100 48 96
No % No %
Yes 1 2 2 4
No 49 98 48 96
No of Cases in
Group-A Group-B
NICU Admission No of Cases in
Group-A Group-B
3rd 
POD
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8 A8 23 42231 UB G2P1L1 61 162 23.2 84 122/80 18 9.4 EL 250 40 290 84 122/80 18 9.4 No No No
No
9 A9 24 77722 UB G2P1L1 63 160 24.6 84 120/80 16 9.2 EL 220 41 261 86 120/80 16 9 No No No
No
10 A10 22 42139 UB G2P1L1 62 158 24.8 82 110/70 18 8.8 EM 240 50 290 86 110/70 18 8.8 No Vomiting No
No
11 A11 28 80672 UB G2P1L1 48 146 22.5 84 120/70 18 9.2 EL 220 50 270 86 120/70 20 9 No No No
No
12 A12 25 80662 B G2P1L0 65 165 23.9 86 110/80 18 9.4 EL 240 50 290 88 110/80 18 9.4 No No No
No
13 A13 26 80751 B G2P1L1 51 162 19.4 82 116/70 16 8.6 EL 243 50 293 84 110/70 18 8.6 No No No
No
14 A14 23 81729 UB PRIMI 50 160 19.5 82 110/80 18 8.8 EL 220 40 260 86 110/80 18 8.6 No No No
No
15 A15 28 42307 B G2P1L0 54 166 19.6 84 110/70 20 8.8 EM 230 43 273 84 110/70 20 8.8 No Fever No
No
16 A16 21 81230 UB G2P1L1 48 148 21.9 86 120/80 20 8.6 EL 230 42 272 86 120/80 20 8.6 No No No
No
17 A17 28 81499 UB G2P1L1 57 161 22 84 120/70 16 8.4 EM 440 67 507 84 120/70 16 8.4 Yes Vomiting No
No
18 A18 29 42316 B G2P1L1 55 165 20.2 82 122/80 18 10.2 EL 260 40 300 86 120/80 20 10 No No No
No
19 A19 23 42347 UB G2P1L1 48 150 21.3 82 110/70 20 8.8 EL 240 40 280 84 110/70 20 8.8 No No No
No
20 A20 23 42359 UB PRIMI 45 148 20.5 82 126/76 18 9.2 EM 230 45 275 84 120/70 18 9 No No No
No
21 A21 25 42383 B G2P1L1 52 164 19.3 84 120/70 20 9 EM 240 45 285 84 120/70 20 9 No No No
No
22 A22 22 82633 B PRIMI 62 166 22.5 82 110/70 18 8.8 EL 242 43 285 85 110/70 18 8.8 No No No
No
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23 A23 26 87580 B G2P1L1 44 143 21.5 82 114/82 18 9.4 EL 245 44 289 86 110/80 18 9.2 No No No
No
24 A24 25 82245 UB G2P1L1 49 142 24.3 84 120/80 20 8.6 EM 252 42 294 87 120/80 22 8.6 No No yes
No
25 A25 24 82513 B G2P1L1 55 151 24.1 86 122/86 18 10.4 EL 250 40 290 89 122/86 18 10.2 No No No
No
26 A26 24 81471 UB G2P1L1 53 148 24.2 80 116/86 20 8.8 EM 246 52 298 80 110/70 20 8.4 No No No
No
27 A27 27 83061 B G2P1L1 55 150 24.4 82 110/70 16 9 EM 235 52 287 84 110/70 16 8.8 No No No
No
28 A28 28 84297 UB G2P1L1 57 153 24.3 84 114/82 18 9 EL 244 46 290 86 114/82 20 9 No No No
No
29 A29 22 84307 UB G2P1L1 52 153 22.2 80 110/70 20 9 EL 239 51 290 84 110/70 20 9 No No No
No
30 A30 22 83408 UB PRIMI 61 164 22.7 82 120/70 20 9.6 EL 247 46 293 86 124/70 20 9.4 No No No
No
31 A31 29 42524 B G2P1L1 58 160 22.7 84 122/80 18 9 EL 250 40 290 86 122/80 18 9 No No No
No
32 A31 21 42467 B PRIMI 51 152 22.1 80 110/70 18 10.6 EM 243 49 292 82 110/70 18 10.4 No No No
No
33 A33 22 86536 UB PRIMI 60 164 22.3 80 120/80 22 9 EL 251 43 294 84 110/70 22 9 No Vomiting No
No
34 A34 25 42476 B G2P1L1 62 162 23.6 82 116/82 18 8.6 EL 245 51 296 84 110/80 18 8.6 No No No
No
35 A35 26 42486 UB G2P1L1 58 165 21.3 84 110/80 20 9 EL 238 52 290 84 110/80 20 9 No No No No
36 A36 26 84508 B G2P1L1 61 172 20.6 82 110/70 18 10.2 EL 238 41 279 84 110/70 18 10 No No No No
37 A37 26 87262 UB G2P1L1 66 168 23.4 80 120/70 20 9.2 EM 246 42 288 82 120/70 20 9.2 No No No
No
38 A38 19 85591 UB PRIMI 57 158 22.8 82 110/80 18 9.8 EL 248 52 300 84 110/80 18 9.8 No Vomiting No
No
39 A39 19 87047 UB PRIMI 48 160 18.8 80 112/70 20 8.8 EL 251 47 298 82 114/70 20 8.8 No No No No
40 A40 24 87001 UB PRIMI 49 159 19.4 86 110/70 18 10 EM 252 45 297 88 110/70 18 9.8 No No No
No
41 A41 27 87009 B G2P1L1 60 162 22.9 82 120/70 20 8.8 EL 245 56 301 82 120/70 20 8.8 No No No
No
42 A42 27 42556 B G2P1L1 61 164 22.7 80 110/80 18 10 EL 252 40 292 80 110/80 18 10 No No No
No
43 A43 30 86506 UB G2P1L1 56 158 22.4 84 114/86 20 8.6 EM 255 46 301 86 114/86 20 8.6 No No No
No
44 A44 35 84291 B G2P1L1 58 160 22.7 82 110/70 18 8.6 EL 258 39 297 84 110/70 18 8.6 No No No
No
45 A45 23 42524 B G2P1L1 61 162 23.2 80 110/70 18 8.6 EM 241 46 287 82 110/70 18 8.6 No Vomiting No
No
46 A46 28 87238 UB G2P1L0 51 162 19.4 84 120/80 20 9.6 EL 252 39 291 84 120/80 20 9.6 No No No
No
47 A47 29 86735 UB G2P1L1 50 160 19.5 82 110/80 18 8.8 EL 249 36 285 84 110/80 18 8.8 No No No
No
48 A48 23 42633 UB PRIMI 54 166 19.6 80 120/76 18 8.4 EL 248 55 303 82 120/78 18 8.4 No No No
No
49 A49 23 42475 B G2P1L1 48 148 21.9 82 110/70 20 8.6 EL 251 41 292 84 110/70 20 8.6 No No No
No
50 A50 23 42614 B G2P1L1 57 161 22 80 120/80 18 9 EM 252 46 298 82 120/80 18 9 No No No
No
51 B1 23 42060 UB PRIMI 55 163 20.7 82 110/70 18 8.8 EL 355 96 451 88 110/70 18 8.4 No No No
No
52 B2 29 79376 B G2P1L1 48 150 21.3 82 122/80 16 9 EL 349 80 429 90 110/70 16 8.6 No No No
No
53 B3 27 79015 UB PRIMI 45 153 19.2 86 116/72 18 10.6 EM 335 76 411 92 110/70 18 9.8 No No No
No
54 B4 25 79662 UB PRIMI 52 162 19.8 80 120/80 16 9 EL 343 78 421 88 110/70 16 8.4 No No No
No
55 B5 30 79092 B PRIMI 62 161
23.9
82 120/80 18 9.2 EL 351 78 429 90 110/70 18 8.8 No No No
No
56 B6 21 78309 UB PRIMI 44 148
20.1
80 120/86 20 9.8 EL 349 79 428 88 120/80 20 9 No No No
No
57 B7 20 79416 UB PRIMI 49 160
19.1
84 120/80 16 8.6 EM 452 86 538 82 110/70 18 8 Yes Vomiting No
No
58 B8 23 80639 UB G2P1L1 55 155
22.9
80 118/82 18 9 EM 341 71 412 86 110/80 18 8.6 No No No
No
59 B9 24 81166 UB G2P1L1 53 157
21.5
82 120/80 16 8.8 EL 353 72 425 88 110/70 16 8.4 No No No
No
60 B10 26 42317 B G2P1L1 55 161
21.2
80 122/78 16 9.2 EL 349 82 431 88 120/70 16 8.8 No No No
No
61 B11 27 42338 UB G2P1L1 57 158
22.8
82 120/80 16 9.6 EL 330 78 408 88 110/70 16 9 No No No
No
62 B12 25 81981 UB PRIMI 52 157
21.1
80 126/82 18 9.6 EL 328 92 420 88 124/80 18 9 No No No
No
63 B13 24 81219 UB G2P1L1 61 162
23.2
86 120/70 18 9.2 EL 342 86 428 92 110/70 18 8.8 No No No
No
64 B14 19 82411 UB PRIMI 58 160
22.7
84 120/80 16 9 EM 458 92 550 92 110/70 20 8.4 Yes Vomiting No
yes
65 B15 24 82619 B G2P1L1 57 159
22.5
82 120/70 18 9.2 EL 340 70 410 86 118/70 18 9 No No No
No
66 B16 29 82394 UB G2P1L1 60 161
23.1
80 120/80 20 8.8 EM 342 76 418 88 110/70 20 8.4 No Fever No
No
67 B17 20 77732 UB G2P1L1 62 162
23.6
82 110/86 18 9.2 EL 353 81 434 88 110/80 18 8.8 No No No
No
68 B18 25 42298 UB G2P1L1 58 162
22.1
80 110/80 20 8.8 EL 456 96 552 90 110/70 20 8.4 Yes No No
No
69 B19 27 82417 B G2P1L1 61 165
22.4
82 120/80 18 9.8 EL 345 74 419 88 120/80 18 9.4 No No No
No
70 B20 27 42328 B G2P1L0 66 164
24.5
84 126/84 20 10 EM 353 73 426 88 120/80 20 9 No No yes
No
71 B21 29 82491 UB PRIMI 57 158
22.8
82 120/80 20 8.8 EL 340 70 410 86 120/80 20 8.6 No No No
No
72 B22 20 82897 B G2P1L1 60 163
22.6
80 110/80 22 9.2 EL 351 78 429 88 110/70 22 8.8 No No No
No
73 B23 18 83007 UB PRIMI 55 157
22.3
80 110/70 20 9.2 EL 356 82 438 88 110/70 20 8.8 No No No
No
74 B24 24 83001 UB G2P1L1 60 158
24
82 114/78 20 10 EM 362 70 432 88 110/70 20 9 No No No
No
75 B25 25 82891 B G2P1L0 54 159
21.4
88 110/70 22 10 EL 345 74 419 92 110/70 22 9.2 No No No
No
76 B26 20 83230 UB PRIMI 56 158
22.4
86 120/80 20 8.6 EM 440 92 532 96 110/70 20 8 Yes Vomiting No
yes
77 B27 28 42286 UB G2P1L1 64 166
23.2
84 116/78 20 10 EL 361 76 437 90 110/70 20 9.2 No No No
No
78 B28 27 42333 B G2P1L1 58 160
22.7
80 120/80 18 9.6 EL 341 78 419 88 110/80 18 9 No No No
No
79 B29 27 42206 UB G2P1L1 60 158
24
86 120/78 18 9.8 EL 352 86 438 92 120/70 18 9 No No No
No
80 B30 26 83236 UB G2P1L1 54 153
23.1
84 120/80 22 8.6 EL 359 88 447 92 110/70 22 8 No No No
No
81 B31 22 81815 B PRIMI 62 158
24.8
80 110/80 18 9.6 EM 347 81 428 86 110/80 18 9.2 No Fever yes
No
82 B31 26 84275 UB G2P1L1 58 161
22.4
82 110/80 20 9.2 EL 338 78 416 80 110/80 20 8.8 No No No
No
83 B33 20 84204 UB G2P1L1 60 162
22.9
80 110/80 18 9.4 EL 345 75 420 82 110/70 18 9 No No No
No
84 B34 23 84131 UB G2A1 57 165
20.9
84 122/86 16 9.8 EL 356 86 442 88 120/80 16 9 No No No
No
85 B35 22 83996 B PRIMI 56 151
24.6
82 120/80 18 9.6 EL 330 88 418 86 120/80 18 9 No No No
No
86 B36 23 84056 UB PRIMI 52 154 21.9 80 120/70 16 9 EL 360 76 436 90 110/70 16 8 No No No No
87 B37 21 83292 B PRIMI 56 157
22.7
82 120/80 18 9.2 EL 353 74 427 86 120/80 18 8.8 No No No
No
88 B38 21 83080 B G2P1L1 61 160
23.8
82 110/80 20 9.8 EM 341 81 422 88 110/80 20 9 No Fever No
No
89 B39 23 83411 UB G2P1L1 62 160
24.2
84 120/70 18 8.8 EL 340 72 412 70 120/70 18 8.6 No No No
No
90 B40 23 83482 B G2P1L1 57 163
21.5
82 120/80 16 9 EL 341 79 420 86 120/80 16 8.6 No No No
No
91 B41 35 83456 B G2P1L1 50 150
22.2
82 110/80 18 9 EL 351 72 423 84 110/70 18 8.6 No No No
No
92 B42 21 84243 B PRIMI 54 154
22.8
86 110/86 20 8.8 EL 339 70 409 90 110/86 20 8.8 No No No
No
93 B43 21 83644 UB PRIMI 55 154
23.2
82 110/70 18 10 EM 351 85 436 88 110/70 18 9.6 No Fever No
No
94 B44 27 83733 B G2P1L1 54 152
23.4
80 110/80 20 9.2 EL 344 85 429 88 110/80 20 9 No No No
No
95 B45 29 84944 B G2P1L1 50 150
22.2
78 110/70 18 9 EL 351 69 420 86 110/70 18 8.6 No No No
No
96 B46 22 85058 B G2P1L0 56 154
23.6
82 110/80 20 9.4 EL 343 73 416 80 110/80 20 9.2 No No No
No
97 B47 28 84745 B G2A1 57 161
22
80 122/76 18 8.8 EL 336 72 408 76 122/76 18 8.8 No No No
No
98 B48 33 85099 UB G2A1 56 158
22.4
86 110/80 16 8.8 EL 340 72 412 88 110/80 16 8.6 No No No
No
99 B49 24 85185 B G2P1L1 48 154
20.2
82 120/82 18 8.6 EL 352 81 433 86 120/82 18 8.6 No No No
No
100 B50 23 84867 B G2P1L1 52 154
21.9
82 110/80 20 9.6 EL 351 71 422 86 110/70 20 9 No No No
No
